Combining zanidatamab, FOLFOX, and pembrolizumab as first-line therapy for HER2/PD-L1–positive gastroesophageal adenocarcinoma—the IKF-t90/AIO/ZANGEA trial with translational analysis

Background Gastroesophageal adenocarcinoma (GEA) remains a major global health burden. For metastatic human epidermal growth factor receptor 2 (HER2)/programmed death-ligand 1 (PD-L1)-positive disease, first-line treatment includes platinum/fluoropyrimidine chemotherapy with trastuzumab and pembrolizumab. In the phase III HERIZON-GEA-01 trial, zanidatamab, a HER2-directed bispecific antibody, demonstrated improved progression-free survival (PFS) and overall survival (OS) combined with chemotherapy and tislelizumab compared with chemotherapy and trastuzumab. HERIZON did not study FOLFOX chemotherapy or pembrolizumab, commonly used treatments in clinical practice. Thus, the ZANGEA trial is evaluating zanidatamab plus modified FOLFOX (mFOLFOX) and pembrolizumab as first-line therapy for HER2/PD-L1-positive GEA. Patients and methods ZANGEA is a prospective, open-label, single-arm, multinational, phase II trial with a translational research program enrolling ∼80 patients with untreated metastatic HER2/PD-L1-positive GEA. Patients receive zanidatamab in combination with mFOLFOX and pembrolizumab. The primary endpoint is the 12-month PFS rate. Secondary endpoints include objective response rate, disease control rate, duration of response, PFS, OS, safety, tolerability, health-related quality of life, and translational correlates. Biomarker analyses include blood-based immune markers, neutrophil-to-lymphocyte ratio, dietary patterns, and microbiota (metabolite) composition associated with response or adverse events, particularly diarrhea. Results Recruitment started in January 2026. As of September 2026, 19 patients have been enrolled and completion of accrual is expected by the end of 2027. No results are currently available. Conclusion ZANGEA will assess the clinical activity and safety of zanidatamab plus mFOLFOX and pembrolizumab in first-line HER2/PD-L1-positive metastatic GEA and may identify biomarkers to guide patient selection and toxicity management.

Authors

Institutions

Publication Details

Journal
ESMO Gastrointestinal Oncology
Published
2026-11-18
DOI
https://doi.org/10.1016/j.esmogo.2026.100444
Primary Topic
Gastric Cancer Management and Outcomes
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Combining zanidatamab, FOLFOX, and pembrolizumab as first-line therapy for HER2/PD-L1–positive gastroesophageal adenocarcinoma—the IKF-t90/AIO/ZANGEA trial with translational analysis

Anke Schlenska‐Lange, Eray Goekkurt, S. Lorenzen, Joseph Tintelnot et al.
5 links
ESMO Gastrointestinal Oncology
Gastric Cancer Management and Outcomes
article

Combining zanidatamab, FOLFOX, and pembrolizumab as first-line therapy for HER2/PD-L1–positive gastroesophageal adenocarcinoma—the IKF-t90/AIO/ZANGEA trial with translational analysis

Anke Schlenska‐Lange, Eray Goekkurt, S. Lorenzen, Joseph Tintelnot, Joao Gorgulho, Dirk Arnold, S-E. Al-Batran, Thorsten Oliver Goetze, Alexander Stein, P.C. Thuss-Patience, V. Rempel, T. Ettrich, K. Heinrich, K. Wegehenkel, A. Kurreck, C. Müller, M. Moehler, U. Lindig, T. Dechow, H. Schmalenberg, N. Homann
article en

Abstract

Background Gastroesophageal adenocarcinoma (GEA) remains a major global health burden. For metastatic human epidermal growth factor receptor 2 (HER2)/programmed death-ligand 1 (PD-L1)-positive disease, first-line treatment includes platinum/fluoropyrimidine chemotherapy with trastuzumab and pembrolizumab. In the phase III HERIZON-GEA-01 trial, zanidatamab, a HER2-directed bispecific antibody, demonstrated improved progression-free survival (PFS) and overall survival (OS) combined with chemotherapy and tislelizumab compared with chemotherapy and trastuzumab. HERIZON did not study FOLFOX chemotherapy or pembrolizumab, commonly used treatments in clinical practice. Thus, the ZANGEA trial is evaluating zanidatamab plus modified FOLFOX (mFOLFOX) and pembrolizumab as first-line therapy for HER2/PD-L1-positive GEA. Patients and methods ZANGEA is a prospective, open-label, single-arm, multinational, phase II trial with a translational research program enrolling ∼80 patients with untreated metastatic HER2/PD-L1-positive GEA. Patients receive zanidatamab in combination with mFOLFOX and pembrolizumab. The primary endpoint is the 12-month PFS rate. Secondary endpoints include objective response rate, disease control rate, duration of response, PFS, OS, safety, tolerability, health-related quality of life, and translational correlates. Biomarker analyses include blood-based immune markers, neutrophil-to-lymphocyte ratio, dietary patterns, and microbiota (metabolite) composition associated with response or adverse events, particularly diarrhea. Results Recruitment started in January 2026. As of September 2026, 19 patients have been enrolled and completion of accrual is expected by the end of 2027. No results are currently available. Conclusion ZANGEA will assess the clinical activity and safety of zanidatamab plus mFOLFOX and pembrolizumab in first-line HER2/PD-L1-positive metastatic GEA and may identify biomarkers to guide patient selection and toxicity management.

ESMO Gastrointestinal OncologyVol. 14
Goethe University Frankfurt (DE), Universität Hamburg (DE), Johannes Gutenberg University Mainz (DE), TUM Klinikum (DE), LMU Klinikum (DE), Humboldt-Universität zu Berlin (DE), Asklepios Klinik Altona (DE), Städtisches Klinikum Dresden (DE), University Medical Center of the Johannes Gutenberg University Mainz (DE), Klinik und Poliklinik für Psychosomatische Medizin und Psychotherapie (DE), University Medical Center Hamburg-Eppendorf (DE), Vivantes Klinikum (DE), München Klinik (DE), Krankenhaus Barmherzige Brüder (DE), Institute of Clinical Cancer Research (DE), Klinikum Bielefeld (DE), University Hospital Frankfurt (DE), Krankenhaus Nordwest (DE), Jena University Hospital (DE), Fraunhofer Project Centre Wolfsburg (DE), Kliniken Essen-Mitte (DE), Klinikum im Friedrichshain (DE), University Hospital Ulm (DE), St. Anna Hospital (DE), Frankfurt Cancer Institute (DE), Technical University of Munich (DE), Freie Universität Berlin (DE), Charité - Universitätsmedizin Berlin (DE), Ludwig-Maximilians-Universität München (DE)
Jazz Pharmaceuticals
Good health and well-being
Gastric Cancer Management and Outcomes
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon